Overview

Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Status:
Not yet recruiting

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous fixed-dose combination) and T-DM1, for patients with previously untreated HER2-positive early breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

MedSIR

Collaborator:

Hoffmann-La Roche

Treatments:

Pertuzumab
Trastuzumab